iOMEDICO will be represented at the ESMO congress in Madrid with numerous contributions:
- 4 contributions with data from our tumor registries
- 5 contributions with data from our study projects
We are particularly pleased about the presentation of the SWITCH-II study as a talk.
See you soon in Madrid!
The relevance of the data from the iOMEDICO tumor registries is highly acknowledged both nationally and internationally. Virtually at the same time, two full publications with data from the tumor registry mammary carcinoma were accepted in international journals:
1. The Breast
Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., Marschner, N., 2017.
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – results from the prospective German TMK cohort study.
The Breast 34, 122–130. Abstract
2. Breast Cancer Research and Treatment
Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Jänicke, M., Marschner, N., TMK-Group (Tumour Registry Breast Cancer), 2017.
Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer – results from the MaTox project.
Breast Cancer Res Treat [Epub ahead of print]. Abstract
You can find more under Publications.
We congratulate all authors and those who contributed!
Every year, the data from the tumour registries become more comprehensive, and their scientific impact and international appreciation grows. Recently, a publication with analyses from the TMK registry about bone metastases in breast cancer was accepted by the European Journal of Cancer.
- First study with data from clinical routine on incidences, patterns of metastasis and survival of patients with bone metastases.
- Almost 90% of patients receive an osteoprotective therapy – usually over the entire course of the disease
- Patterns of metastasis and survival vary according to the tumour’s receptor status.
The project of developing a training network for immune therapy research received the acceptance for funding through the HORIZON 2020 Program for Research and Innovation. iOMEDICO supports the project gratuitously by accommodating and supervising five Next-Generation-Researchers of immune therapy of tumours. Further cooperating partners are universities, foundations and an immune therapeutical biotech company operating in the Netherlands, Great Britain/Scotland and Spain.
The follow-up on the OnkoRat 2017 is complete, and we received numerous positive responses. You can find a detailed review of the event on the OnkoRat website: http://onkorat.com
For the paper-free patient surveys in iOMEDICO projects, 110 study sites are now equipped with the PRO Patient system. The data is documented directly in the waiting room, using tablet computers. A time-efficient approach for everyone.
A series of research projects is already using the system: PRO Bone, PRO Kidney, PROXie, CARO and STEFANO. Further projects are in the planning stage.
The first feedback is outstanding: The exchange on equal footing about current research results and future-oriented study concepts was constructive and offered varied impulses for all participants. The atmosphere was excellent and the event a great success.
We are looking forward to seeing you all again next year. A detailed review will be published shortly.
The registration hotline for the nationwide scientific study symposium has been busy. Over 100 oncologists and haematologists participating in clinical studies have already registered for this meeting. This is a fantastic development and wonderful feedback on the OnkoRat symposium.
The OnkoRat symposium 2017 will take place in Frankfurt am Main on 31st March and 1st April 2017. Please visit the Event Website (http://onkorat.com) for further information.
Come and join us! We look forward to two days of intensive scientific exchange.
The results of both the BRd study and the Treosulfan study have been issued:
- The full-length article on the results of the BRd study has been published in the British Journal of Haematology. (Bendamustine, lenalidomide and dexamethasone has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma – a phase II trial)
- The results of the Treosulfan study have been published in the Journal of Cancer Research and Clinical Oncology. The data on efficacy and safety of oral vs. intravenous Treosulfan administration in recurrent ovarian carcinoma are available online (http://link.springer.com/article/10.1007%2Fs00432-016-2307-0)
Further publications are available using the following link: Publications
Every year in spring, clinical research experts participating in clinical studies meet to discuss current research findings, initiate projects and collaborations. The 6th OnkoRat symposium will take place in Frankfurt am Main on 31st March and 1st April 2017.
A wide variety of interesting lectures are on the agenda spanning from ctDNA, miRNA, biomarker profiling across apoptosis induction and cell cycle arrest to Real-World Data and the influence of demographic changes.
Workshops on oncological indications, in which questions relevant to clinical studies are being discussed and explored, are a familiar feature and well integrated into the program. New to this year’s program is the Oncological Quartet. Professor Dieter Hossfeld will discuss the financial viability of molecular oncology together with three other speakers – critical and plain, controversial and blunt.
Further information is available at the Event Website.
We are looking forward to your coming!
Full-length publication on the overall survival of “real-life” patients versus patients in clinical trials
“Real-life” patients, such as the patients in the tumour registry of advanced renal cell carcinoma, often do not fulfil the strict inclusion criteria in clinical trials and are therefore considered “trial inappropriate”. An analysis in the tumour registry of renal cell carcinoma showed that this applies to almost 60% of all mRCC patients in clinical routine practice in Germany. Compared to patients from clinical trials the overall survival of “trial inappropriate” patients is clearly lower. The data analysis was recently published in Clinical Genitourinary Cancer.
Queries can be avoided. Please observe all relevant instructions when initially submitting the notification. Our SAE brochure provides a brief guide to prevent unnecessary and, above all, urgent questions, i.e. queries. The brochure can be located in the Download Area.
It is here! Our new homepage has gone live. We are delighted to have a new corporate design that represents us, our tasks and activities. This is us – iOMEDICO.
Feedback and comments are very welcome (E-Mail: firstname.lastname@example.org)
Patient-reported outcome (PRO) and, in particular, quality of life complement clinical data and are becoming increasingly important in clinical research. The PRO Patient System provides a paperless documentation for patient questionnaires. Using tablet PCs, patient interviews can already be carried out in waiting rooms. This is a mobile health tool developed for patients.
In the beginning of December 2016, the PRO Patient System was successfully installed at the 100th centre. PROs are collected by using this system in various research projects including PRO Bone, PRO Kidney, PROX, CARO, and Stefano. Further PRO projects are in the planning stage.